Quantifying trade-offs: Quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer

British Journal of Cancer

Volumn 91, Issue 11, 2004, Pages 1893-1901

  Bernhard, J ^a,b   Zahrieh, D ^c,d   Coates, A S ^e,f   Gelber, R D ^c,d   Castiglione Gertsch, M ^a   Murray, E ^g,h   Forbes, J F ^i,j   Perey, L ^k   Collins, J ^l   Snyder, R ^m   Rudenstam, C M ⁿ   Crivellari, D ^o   Veronesi, A ^o   Thurlimann B ^p   Fey, M F ^b   Price, K N ^b   Goldhirsch, A ^q,r   Hurny C ^s  

^a IBCSG Coordinating Center   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e Cancer Council Australia   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ Australian NZL Breast Cancer T G   (Australia)

^j NEWCASTLE MATER HOSPITAL   (Australia)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l ROYAL MELBOURNE HOSPITAL   (Australia)

^m ST VINCENT S HOSPITAL   (Australia)

ⁿ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^o CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^p CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^q ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^r EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^s Bürgerspital   (Switzerland)

more..

Author keywords

Adjuvant therapy; Breast cancer; Q TWiST; Quality of life; Quality adjusted survival; Utility

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; APPETITE; ARM MOVEMENT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COPING BEHAVIOR; FATIGUE; FEMALE; HEALTH STATUS; HOT FLUSH; HUMAN; INTERNATIONAL BREAST CANCER STUDY GROUP QUALITY OF LIFE CORE FORM; MAJOR CLINICAL STUDY; MASTECTOMY; MOOD; NAUSEA; OPIOID INDUCED EMESIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY ADJUSTED SURVIVAL; QUALITY OF LIFE; QUALITY OF LIFE WITHOUT SYMPTOMS AND TOXICITY; SELF EVALUATION; SOCIAL SUPPORT; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

EID: 19944428970     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602230     Document Type: Article

References (43)

1. Ashby J, O Hanlon M, Buxton MJ (1994) The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Qual Life Res 3: 257-265
2. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien BJ (1999) Are health states 'timeless'? The case of the standard gamble method. J Clin Epidemiol 52: 1047-1053
3. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM (1997) Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol 8: 825-835
4. Bernhard J, Lowy A, Maibach R, Hürny C (2001) Response shift in the perception of health for utility evaluation. An explorative investigation. Eur J Cancer 37: 1729-1735
5. Bernhard J, Thürlimann B, Schmitz SF, Castiglione Gertsch M, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C (1999) Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol 17: 1672-1679
6. Bleichrodt H, Johannesson M (1997) The validity of QALYs: an experimental test of constant proportional tradeoff and utility independence. Med Decis Making 17: 21-32
7. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR (2000) Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 18: 743-753
8. Broeckel JA, Jacobsen PB, Balducci L, Horton J, Lyman GH (2000) Quality of life after adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 62: 141-150
9. Broeckel JA, Thors CL, Jacobsen PB, Small M, Cox CE (2002) Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy. Breast Cancer Res Treat 75: 241-248
10. Butow P, Coates A, Dunn S, Bernhard J, Hürny C (1991) On the receiving end IV: validation of quality of life indicators. Ann Oncol 2: 597-603
11. Cole BF, Gelber RD, Gelber S, Mukhopadhyay P (2004) A quality-adjusted survival model (Q-TWiST) for advanced stage cancer. J Biopharm Stat 14: 111-124
12. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B (1999) Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 17: 2659-2669
13. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18: 3302-3317
14. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM (1999) Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res 8: 723-731
15. Fallowfield L, Fleissig A, Edwards R, West A, Powles TJ, Howell A, Cuzick J (2001) Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19: 1885-1892
16. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J (2001) Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'well-tolerated' treatments? Breast Cancer Res Treat 66: 73-81
17. Ganz PA, Desmond KA, Leedham BL, Rowland JH, Meyerowitz BE, Belin TR (2002) Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94: 39-49
18. Giesler RB, Ashton CM, Brody B, Byrne MM, Cook K, Geraci JM, Hanita M, Souchek J, Wray NP (1999) Assessing the performance of utility techniques in the absence of a gold standard. Med Care 37: 580-588
19. Glasziou PP, Cole BF, Gelber RD, Hilden J, Simes RJ (1998) Quality adjusted survival analysis with repeated quality of life measures. Stat Med 17: 1215-1229
20. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS, for the Ludwig Breast Cancer Study Group (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7: 36-44
21. Hürny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A, Senn HJ, for the Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG) (1993) The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer 1: 200-208
22. Hürny C, Bernhard J, Coates A, Castiglione M, Peterson HF, Gelber RD, Rudenstam CM, Goldhirsch A, Senn HJ (1994) Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Ann Oncol 5: 65-74
23. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ (1996a) Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care 34: 234-248
24. Hürny C, Bernhard J, Coates AS, Castiglione Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ (1996b) Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet 347: 1279-1284
25. Hürny C, van Wegberg B, Bacchi M, Bernhard J, Thürlimann B, Real O, Perey L, Bonnefoi H, Coates A (1998) Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials. Br J Cancer 77: 985-991
26. International Breast Cancer Study Group (2002) Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 94: 1054-1065
27. Jansen SJ, Kievit J, Nooij MA, de Haes JC, Overpelt IM, van Slooten H, Maartense E, Stiggelbout AM (2001a) Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 84: 1577-1585
28. Jansen SJ, Kievit J, Nooij MA, Stiggelbout AM (2001b) Stability of patients' preferences for chemotherapy: the impact of experience. Med Decis Making 21: 295-306
29. Jansen SJ, Stiggelbout AM, Wakker PP, Nooij MA, Noordijk EM, Kievit J (2000) Unstable preferences: a shift in valuation or an effect of the elicitation procedure? Med Decis Making 20: 62-71
30. Joly F, Espie M, Marty M, Heron JF, Henry Amar M (2000) Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy. Br J Cancer 83: 577-582
31. Lindley C, Vasa S, Sawyer WT, Winer EP (1998) Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol 16: 1380-1387
32. Llewellyn-Thomas HA, Sutherland HJ, Thiel EC (1993) Do patients' evaluations of a future health state change when they actually enter that state? Med Care 31: 1002-1012
33. Llewellyn-Thomas HA, Thiel EC, McGreal MJ (1992) Cancer patients' evaluations of their current health states: the influences of expectations, comparisons, actual health status, and mood. Med Decis Making 12: 115-122
34. Lowy A, Bernhard J (2004) Quantitative assessment of changes in patients' constructs of quality of life: an application of multilevel models. Qual Life Res 13: 1177-1185
35. O'Connor AM, Boyd NF, Warde P, Stolbach L, Till JE (1987) Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. J Chronic Dis 40: 811-818
36. Phillips KA, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95: 190-197
37. Ravdin PM, Siminoff IA, Harvey JA (1998) Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16: 515-521
38. Sadler IJ, Jacobsen PB (2001) Progress in understanding fatigue associated with breast cancer treatment. Cancer Invest 19: 723-731
39. Simes RJ, Coates AS (2001) Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? J Natl Cancer Inst Monogr 30: 146-152
40. Stiggelbout AM, Kiebert GM, Kievit J, Leer JW, Habbema JD, De Haes JC (1995) The 'utility' of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 48: 1207-1214
41. The International Breast Cancer Study Group (2001) Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 10: 130-138
42. Torrance GW, Feeny D, Furlong W (2001) Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 21: 329-334
43. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q (1996) Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 34: 702-722